Maine Medicine Weekly Update - April 16, 2021  (Plain Text Version)

Return to Graphical Version

In this issue:
•  Maine Medical Association Statement on Johnson & Johnson COVID-19 Vaccine Pause
•  FDA Update & Statement on Johnson & Johnson COVID-19 Vaccine Pause Recommendation
•  Thrombotic Thrombocytopenia & J&J COVID Vaccine — Response from the Manufacturer
•  Over 30 Percent of US Adults Fully Vaccinated, Maine Leads the Nation
•  Maine CDC COVID-19 Update for Clinicians with Stephen Sears, MD
•  Clinical Updates and Guidance Related to COVID-19
•  Medicare FFS Claims: 2% Payment Adjustment (Sequestration) Suspended Through December
•  MaineCare Updates: Upcoming Accountable Communities Public Webinar & Primary Care 2.0 Presentation Available Online
•  HealthCare Dive: Urgent Care Centers Draw Some ER Visits but Associated with Higher Spending Overall
•  Webinar for Medical Students April 22: So You Are Employed, Now What?
•  Next MMA Legislative Call Will Be Wednesday, April 21st
•  Maine Community Action Partnership is Working for a Successful Vaccine Roll Out for All
•  Maine Medical Association & ActionPPE Partner Again; This Time for FDA Approved Rapid Antigen Tests
•  A Message from Maine Responds: Volunteer Opportunity
MAINE LEGISLATURE
•  Maine Legislature Week 14 Update
•  Maine Legislature Public Hearings, Work Sessions & New Bills
UPCOMING EVENTS
•  Upcoming Specialty Society Meetings
•  Maine CDC Physicians To Host Regular Clinician COVID Vaccine Info Sessions
•  "Prescribing to Reduce Opioid Overdose Risk: How to Impact the Epidemic Within the Pandemic"
•  NAMI Maine Workshops in May & June: Suicide Prevention & Management for Clinical Staff
•  AAP EQIPP Course: Immunizations - Strategies for Success (for RURAL Health Providers)
•  New Maine AAP Educational Webinar Series
HEALTHCARE EMPLOYMENT OPPORTUNITIES
•  Nurse Practitioner
•  Executive Director
•  Medical Director - ME License Required
•  Practice Administrator
•  Physician
•  Psychiatric Nurse Practitioner

Thrombotic Thrombocytopenia & J&J COVID Vaccine — Response from the Manufacturer

The following letter from the manufacturer of Janssen Vaccines and Prevention, Leiden was published April 16, 2021 online by the New Journal of Medicine.

The following letter from the manufacturer of Janssen Vaccines and Prevention, Leiden was published April 16, 2021 online by the New Journal of Medicine. 

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination